Scientists Discover Which Immune Cells Drive Multiple Sclerosis—And It Could Change Treatment

Researchers have pinpointed the exact immune cells responsible for triggering multiple sclerosis (MS), identifying 61 genes involved in the disease process. This breakthrough could reshape how doctors treat MS by enabling more precise therapies that target the root cause rather than broadly suppressing the immune system. The study used advanced genetic analysis to establish definitive causal links between B cells, dendritic cells, and MS development—moving beyond previous observational research that couldn't prove cause-and-effect relationships.

What Are B Cells and Dendritic Cells, and Why Do They Matter in MS?

Multiple sclerosis is a chronic autoimmune disease where the immune system mistakenly attacks the protective coating around nerve fibers in the brain and spinal cord, causing inflammation and damage. For decades, researchers knew immune cells played a role, but they couldn't definitively prove which ones were the culprits. This new study used Mendelian randomization—a sophisticated genetic technique that analyzes DNA data to establish true cause-and-effect relationships—to identify B cells and dendritic cells as key drivers of MS susceptibility.

B cells are immune cells that produce antibodies, while dendritic cells act as messengers that alert other immune cells to potential threats. The research revealed that these cells contribute to MS through a specific mechanism: B-cell antigen presentation and pathways involving human leukocyte antigen (HLA)—proteins that help the immune system recognize self versus foreign substances. When this system malfunctions, it can trigger the autoimmune attack characteristic of MS.

How Could This Research Lead to Better MS Treatments?

Current MS treatments often use anti-B cell monoclonal antibodies—drugs that broadly eliminate B cells throughout the body. While effective at reducing MS symptoms, these medications can cause significant side effects because they disrupt normal immune function. The new findings suggest a more targeted approach: instead of eliminating all B cells, doctors could potentially develop therapies that specifically block the problematic antigen presentation pathways without affecting other immune functions.

The study identified 61 pleiotropic genes—genes that influence multiple traits—associated with MS. Understanding these genes and their roles in disease development opens doors to precision medicine approaches. Researchers also observed that immune cell populations change after MS onset, suggesting these alterations could serve as biomarkers for early diagnosis, allowing doctors to identify and treat the disease before significant neurological damage occurs.

Steps to Understanding Your MS Risk and Treatment Options

• Genetic Counseling: If you have a family history of MS or other autoimmune diseases, speak with a genetic counselor about your inherited risk factors and what genetic testing might reveal about your susceptibility.
• Immune Cell Monitoring: Ask your neurologist whether tracking changes in your immune cell populations could help with early detection or treatment monitoring, as the research suggests these alterations may serve as diagnostic markers.
• Targeted Therapy Discussion: When considering MS treatment options, discuss with your doctor whether emerging precision therapies targeting specific immune pathways might be appropriate for your disease profile, rather than broad immunosuppression.
• Regular Neurological Assessment: Maintain consistent follow-up appointments to monitor cognitive function and disease progression, as early intervention based on immune biomarkers may prevent long-term disability.

What About Cognitive Problems in MS—Is There a Connection?

Beyond immune mechanisms, MS causes significant cognitive challenges that affect quality of life. Research involving 66 people with MS and 38 healthy controls found that mental fatigue plays a crucial role in cognitive decline. Mental fatigue—a persistent difficulty concentrating and thinking clearly—is reported by 76 to 97 percent of people with MS, with 40 percent identifying it as their most disabling symptom.

The study revealed that mental fatigue acts as a bridge between information processing speed (how quickly the brain processes information) and verbal memory problems. When researchers assessed participants using standardized cognitive tests, people with MS performed significantly worse than healthy controls across all cognitive domains. Importantly, mental fatigue mediated the relationship between processing speed and memory deficits—meaning that as processing speed declined due to MS-related nerve damage, people experienced greater mental exhaustion, which then further impaired their ability to encode and retrieve memories.

This finding has practical implications: interventions targeting mental fatigue could potentially improve cognitive performance in people with MS. Unlike fatigability—an observable decline in task performance that improves with rest—subjective mental fatigue is a persistent, self-reported experience that doesn't necessarily resolve with rest and requires specific management strategies.

Why This Research Matters for the Future of MS Care

The convergence of these findings—identifying specific immune cells driving MS while understanding how the disease affects cognition—paints a more complete picture of multiple sclerosis. Rather than viewing MS as a single disease with one treatment approach, researchers increasingly recognize it as a complex condition involving multiple biological systems. The identification of B cells and dendritic cells as causal factors, combined with understanding how mental fatigue amplifies cognitive decline, suggests that comprehensive MS management should address both immune mechanisms and symptom-specific interventions like fatigue management.

For people living with MS, these advances offer hope. The move toward precision medicine—treatments designed around individual genetic and immune profiles—could mean fewer side effects and better outcomes. Meanwhile, recognizing the role of mental fatigue opens opportunities for cognitive rehabilitation and fatigue-management programs that might help preserve quality of life. As this research translates into clinical practice over the coming years, MS treatment is likely to become increasingly personalized and effective.